BALTIMORE, May 29 /PRNewswire/ -- FASgen Diagnostics, LLC (Baltimore) and Tetracore, Inc. (Rockville) have announced that they have entered into a collaboration to produce cGMP ELISA and IHC tests for cancer biomarkers using FASgen's proprietary antibodies. The tests measure the over-expression of the enzyme fatty acid synthase (FAS), which is found in virtually all solid tumor cancers. FASgen's FAS-detect(TM) Elisa and FAS-detect(TM) IHC tests, currently available for research purposes, have demonstrated repeated and highly significant success in identifying the progression of the disease in a series of different solid tumors, including, pancreas, ovarian, prostate and lung cancer. These research results were recently the subject of multiple independent papers and presentations at the AACR annual meeting and at the earlier annual meeting of the Society of Gynecological Oncologists.
FASgen Diagnostics and Tetracore have been working together for the last six years and the current transaction expands the antibody and kit production role to Tetracore's FDA approved GMP production facility. Tetracore has previously been the primary source of certain new proprietary FASgen antibodies that form the core of the FAS-detect(TM) Elisa and FAS-detect(TM) IHC tests. Tetracore has also been given the opportunity to invest in FASgen Diagnostics. "We welcome the opportunity to expand our working relationship with the FASgen Diagnostics team, and are very pleased that they were willing to select Tetracore as the first outside corporate investor to participate in their Company," said Dr. William Nelson, President of Tetracore Inc. "These FAS diagnostic tests represent a new bio-marker platform test for monitoring cancer and will be highly complementary to existing tests to the benefit of patients and clinicians," said Dr. Frank Kuhajda, Professor of Biochemistry and Pathology at Johns Hopkins Medical School and a Founder of FASgen Diagnostics, and who is also credited with the original discovery of the over expression of FAS in solid tumors.
Scientists at FASgen Diagnostics are part of the consortium of researchers at Johns Hopkins who have been studying the role of over expression of fatty acid synthase in cancer. That work has been underway for more than 15 years. FASgen Diagnostics is the sister company to FASgen, Inc., which is actively developing therapeutics for the treatment of cancer based on the selective inhibition of fatty acid synthase.
Both Dr. Nelson and Dr. Kuhajda stated, "We are very appreciative that we were brought together in the first instance by Eric Stoer, current Chairman of FASgen, Inc. and FASgen Diagnostics, LLC, who helped form Tetracore in 2001 and earlier had helped form FASgen, Inc. and FASgen Diagnostics in 2000. Mr. Stoer has been the catalyst in making both companies successful."
About FASgen Diagnostics, LLC and FASgen, Inc.: FASgen, Inc. is a drug development company founded in 2000 by four distinguished Johns Hopkins researchers to create new therapeutic products based on the selective inhibition of fatty acid biosynthesis. The Company has the exclusive license from Johns Hopkins to more than 15 years of research in the field, which research continues under a sponsored research agreement with the University.
FASgen Diagnostics, LLC, an affiliated company, is a diagnostic company producing research tests for measuring the over expression of FAS in cancer. FAS-detect(TM) IHC and FAS-detect(TM) ELISA are marketed for research purposes.
About Tetracore: Tetracore is a biotechnology company dedicated to the creation of highly innovative diagnostic reagents and assays for infectious diseases and bio-terrorism threat agents. Tetracore's product portfolio focuses on veterinary, domestic preparedness, clinical, antibody and ELISA products, and includes FDA and USDA approved tests.
|SOURCE FASgen Diagnostics, LLC|
Copyright©2008 PR Newswire.
All rights reserved